A study from the University of California, La Jolla, CA, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published in the 15 November 2009 issue of Nature Medicine by Prof. Thistlethwaite PA, Li X and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-based therapy for pulmonary arterial hypertension: Apurinic/Apyrimidinic Endonuclease inhibits the development of pulmonary arterial hypertension via up regulation of its target gene. Together, pharmacological formulations encompassing “Apurinic/Apyrimidinic Endonuclease activators” may be used to treat pulmonary arterial hypertension.
Amount: $ 500*
Undisclosed information: How Apurinic/Apyrimidinic Endonuclease decreases pulmonary arterial hypertension
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, MiRNA-based therapy for pulmonary arterial hypertension: Apurinic/Apyrimidinic Endonuclease inhibits the development of pulmonary arterial hypertension via up regulation of its target gene, 29/November/2014, 22.32, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
